Data Sheet (Cat.No.T5675)

TargetMol

Almonertinib hydrochloride

Chemical Properties



CAS No. : 2134096-03-8

Formula: C30H36ClN7O2

Molecular Weight: 562.1

Storage: Store at low temperature,Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Almonertinib hydrochloride (HS-10296 hydrochloride) is a small molecule inhibitor of EGFR-activating mutations and T790M-resistant mutation with limited activity against wild-type EGFR.
Targets(IC50)	EGFR
In vitro	HS-10296 hydrochloride is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC[1].

Solubility Information

Solubility	DMSO: 83.33 mg/mL (148.25 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (5.87 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.779 mL	8.8952 mL	17.7904 mL
5 mM	0.3558 mL	1.779 mL	3.5581 mL
10 mM	0.1779 mL	0.8895 mL	1.779 mL
50 mM	0.0356 mL	0.1779 mL	0.3558 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ivana S , David P . Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line[J]. Frontiers in Medicine, 2017, 3.

Wu S G , Shih J Y . Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Molecular Cancer, 2018, 17(1):38.